Influenza Drug Market Struggles With Reimbursement Issues and Pandemic Fears
Posted on: Tuesday, 18 April 2006, 09:01 CDT
WALTHAM, Mass., April 18 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the influenza therapeutic drug market is constrained by reimbursement, formulary hurdles, and perceptions of low efficacy of current antivirals. However fears of a future influenza pandemic are driving sales. According to the now available Influenza -- Payer Constraints and Pandemic Fears report, although recent concern over the health impact of an influenza pandemic had increased stockpiling of influenza antivirals in all markets, overall use of influenza antiviral drugs remains low owing to their high cost, inconvenience, and perceived lack of efficacy.
Reimbursement is a hurdle for the influenza drug market as well.
"Despite having failed to achieve reimbursement status in many European Union markets, Roche's Tamiflu is the overwhelmingly dominant product in the market. However, future entrants to this market must demonstrate convincing cost-benefit data to gain favorable reimbursement and widespread usage," said Aaron Woolsey, analyst at Decision Resources.
About Influenza -- Payer Constraints and Pandemic Fears from Decision Resources
Influenza -- Payer Constraints and Pandemic Fears covers the current state of the influenza drug market. The report includes:
* Analysis of the influenza market driven by qualitative interviews with KOLs and survey data from high prescribing physicians defining their target product profile. * Assessment of the influenza market including diagnosed and drug-treated populations, patient share/market share projections, cost per day and compliance estimates. * Discussion of the opportunity for drug developers given the market's relatively large, seasonal patient population, limited efficacy of current therapies and heightened concerns over influenza epidemic. * Examination of payer reluctance to reimburse antivirals for influenza and the reimbursement outlook for drugs with improved efficacy.
The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- The First Book About Marketing Resource Management
- Hagens Berman Sobol Shapiro Announces Investigation into Marketing of Bayer Drugs
- NanoViricides' EKC Eye Drug Demonstrates Significant Therapeutic Efficacy in Initial Animal Trials
- Target Product Profiles 2008 Colorectal Cancer Report Qualitatively Predicts the Market Potential of a Drug Fulfilling a Key Unmet Need
- Web Digest For Marketers Expands Coverage of 6 Key Internet Marketing Resources
- The Market for Antidepressive Drugs Is the Largest Segment of the CNS Sector With Global Sales of US$16.2 Billion in 2005 - 2006 Market Research CNS Drug Discoveries: Depression
- Research and Markets: Recent Changes To Medicare's Drug Reimbursement Policies Have Drastically Altered The Way Treatment Is Financed And Promise To Shape The Future Of Cancer Treatment In The United States
- Questar Market Resources Prices Senior Notes Offering
- Research and Markets: Worldwide Prescription Drug Market for Women's Health Forecast to Grow to $11.6 Billion in 2009
 |
 |
User Comments (0)
RSS Feeds